MySize (NASDAQ: MYSZ) grew Q2 revenue 53% YoY to $3.07M and lifted first-half revenue 57% to $5.46M, but gross margin fell to ~31.7% from ~56.0% due to a lower-margin shift toward commerce. The company reported a Q2 net loss of ~$1.75M (vs ~$450k a year earlier) and operating loss of ~$1.72M (vs ~$586k), while operating cash usage improved to -$1.97M in 1H vs -$2.31M. Management is pivoting toward contribution margin improvement and monetization/efficiency, though it reiterated that it expects ongoing losses and negative operating cash flows and will require additional capital.
This prints as a growth story, but the market should price it as a funding story first. The revenue mix is moving toward lower-quality commerce, so the headline growth likely comes with worse gross conversion and higher customer-acquisition tolls; that is exactly the wrong setup for a microcap with limited balance-sheet flexibility. The SaaS/recommerce pieces are the only parts that can support a higher multiple, but they are still too small to offset dilution risk.
The key second-order effect is financing timing. With cash coverage thin relative to recent operating burn, the company likely needs external capital within months, not years, and the equity story can get reset well before any operating leverage shows up. If management leans into inventory-heavy commerce to chase revenue, working-capital drag could worsen and force a raise on worse terms; if it pivots too hard to margin preservation, growth decelerates and the market loses the only reason to own the name.
Contrarian case: if the next two quarters show gross margin stabilization and a sharp step-down in cash use, the stock can re-rate quickly because expectations are low. But that requires proof, not narrative. The main falsifier for the bearish view is a materially non-dilutive financing package or a sustained inflection in operating cash burn toward sub-$1m per half-year; absent that, any post-print bounce looks sellable.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment